Raymond James Initiates Coverage On Revolution Medicines with Outperform Rating, Announces Price Target of $30
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Dane Leone has initiated coverage on Revolution Medicines (NASDAQ:RVMD) with an Outperform rating and set a price target of $30.
November 16, 2023 | 10:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Revolution Medicines has been given an Outperform rating and a $30 price target by Raymond James, indicating a positive outlook for the stock.
Analyst coverage, especially with an Outperform rating, tends to create a positive sentiment around a stock. The price target of $30 suggests a significant upside potential from the current trading price, which can lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100